Search
Debrisoquine
go.drugbank.com/drugs/DB04840ApprovedIt is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme.
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesFlunarizine
go.drugbank.com/drugs/DB04841ApprovedInvestigationalFlunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and periphe...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 SubstratesRoxadustat
go.drugbank.com/drugs/DB04847ApprovedInvestigationalRoxadustat is a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor used to treat anemia associated with chronic kidney disease. It works by reducing the breakdown of the hypoxia-inducible factor (HIF), which is a transc...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 SubstratesNebivolol
go.drugbank.com/drugs/DB04861ApprovedInvestigationalNebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and di...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesElacridar
go.drugbank.com/drugs/DB04881InvestigationalElacridar (GW120918) is an oral bioenhancer that targets multiple drug resistance in tumors. In many cases, the appearance of multidrug resistance in cancer is due to a change in expression of protein inhibitors. As of August 2007 elacri...
Categories: P-glycoprotein inhibitorsDapoxetine
go.drugbank.com/drugs/DB04884InvestigationalDapoxetine is a selective serotonin reuptake inhibitor, for the treatment of premature ejaculation. In a phase II proof-of-concept study conducted by PPD, dapoxetine demonstrated a statistically significant increase in ejaculatory latenc...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesVapreotide
go.drugbank.com/drugs/DB04894InvestigationalVapreotide is a synthetic octapeptide somatostatin analog. It was being studied for the treatment of cancer.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsXimelagatran
go.drugbank.com/drugs/DB04898ApprovedWithdrawnXimelagatran is an anticoagulant intended to become a replacement for warfarin by overcoming the dietary restrictions, drug interaction, and monitoring issues associated with the former. In 2006, its manufacturer AstraZeneca announced th...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesTesmilifene
go.drugbank.com/drugs/DB04905InvestigationalTesmilifene is a novel potentiator of chemotherapy which, when added to doxorubicin, achieved an unexpected and very large survival advantage over doxorubicin alone in a randomized trial in advanced breast cancer.
Categories: Cytochrome P-450 CYP1A1 Substrates, P-glycoprotein inducersOspemifene
go.drugbank.com/drugs/DB04938ApprovedOspemifene is a new selective non-hormonal estrogen receptor modulator (SERM) that is used for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. FDA approved on February 26, 2013.
Synonyms: 2-(p-((Z)-4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)ethanolCategories: Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 Substrates